As of 2026-03-31, the EV/EBITDA ratio of Sutro Biopharma Inc (STRO) is -2.49. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. STRO's latest enterprise value is 337.83 mil USD. STRO's TTM EBITDA according to its financial statements is -135.84 mil USD. Dividing these 2 quantities gives us the above STRO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.3x - 16.4x | 14.8x |
| Forward P/E multiples | 17.0x - 20.7x | 18.7x |
| Fair Price | (136.68) - (131.72) | (134.74) |
| Upside | -667.1% - -646.6% | -659.1% |
| Date | EV/EBITDA |
| 2026-03-27 | -2.53 |
| 2026-03-26 | -2.59 |
| 2026-03-25 | -2.41 |
| 2026-03-24 | -2.42 |
| 2026-03-23 | -2.15 |
| 2026-03-20 | -2.07 |
| 2026-03-19 | -2.13 |
| 2026-03-18 | -2.21 |
| 2026-03-17 | -2.35 |
| 2026-03-16 | -2.41 |
| 2026-03-13 | -2.36 |
| 2026-03-12 | -2.53 |
| 2026-03-11 | -2.54 |
| 2026-03-10 | -2.65 |
| 2026-03-09 | -2.59 |
| 2026-03-06 | -2.63 |
| 2026-03-05 | -2.29 |
| 2026-03-04 | -2.15 |
| 2026-03-03 | -1.95 |
| 2026-03-02 | -2.06 |
| 2026-02-27 | -2.05 |
| 2026-02-26 | -2.05 |
| 2026-02-25 | -2.04 |
| 2026-02-24 | -1.93 |
| 2026-02-23 | -1.80 |
| 2026-02-20 | -1.80 |
| 2026-02-19 | -1.94 |
| 2026-02-18 | -1.68 |
| 2026-02-17 | -1.58 |
| 2026-02-13 | -1.53 |
| 2026-02-12 | -1.46 |
| 2026-02-11 | -1.47 |
| 2026-02-10 | -1.46 |
| 2026-02-09 | -1.26 |
| 2026-02-06 | -1.45 |
| 2026-02-05 | -1.34 |
| 2026-02-04 | -1.37 |
| 2026-02-03 | -1.37 |
| 2026-02-02 | -1.40 |
| 2026-01-30 | -1.38 |
| 2026-01-29 | -1.38 |
| 2026-01-28 | -1.46 |
| 2026-01-27 | -1.58 |
| 2026-01-26 | -1.46 |
| 2026-01-23 | -1.39 |
| 2026-01-22 | -1.55 |
| 2026-01-21 | -1.48 |
| 2026-01-20 | -1.38 |
| 2026-01-16 | -1.24 |
| 2026-01-15 | -1.15 |